Sen. Carol Ronen

Filed: 2/15/2006

 

 


 

 


 
09400SB2578sam002 LRB094 17772 RAS 56097 a

1
AMENDMENT TO SENATE BILL 2578

2     AMENDMENT NO. ______. Amend Senate Bill 2578 on page 3,
3 immediately below line 28, by inserting the following:
4     "(a) The General Assembly finds that this Section is
5 necessary for the immediate preservation of the public peace,
6 health, and safety."; and
 
7 on page 3, line 29, by replacing "(a)" with "(b)"; and
 
8 on page 3, by replacing lines 32 through 35 with the following:
9 "seizures.
10     "Epilepsy" means a neurological condition characterized by
11 recurrent seizures."; and
 
12 on page 4, by replacing lines 1 through 25 with the following:
13     ""Seizure" means a brief disturbance in the electrical
14 activity of the brain.
15     (c) When the prescribing physician has indicated on the
16 original prescription "dispense as written" or "may not
17 substitute", a pharmacist may not interchange an
18 anti-epileptic drug or formulation of an anti-epileptic drug
19 for the treatment of epilepsy without notification and the
20 documented consent of the prescribing physician and the patient
21 or the patient's parent, legal guardian, or spouse.
 
22     Section 10. The Illinois Food, Drug and Cosmetic Act is

 

 

09400SB2578sam002 - 2 - LRB094 17772 RAS 56097 a

1 amended by changing Section 3.14 as follows:
 
2     (410 ILCS 620/3.14)  (from Ch. 56 1/2, par. 503.14)
3     Sec. 3.14. Dispensing or causing to be dispensed a
4 different drug in place of the drug or brand of drug ordered or
5 prescribed without the express permission of the person
6 ordering or prescribing. Except as set forth in Section 26 of
7 the Pharmacy Practice Act However, this Section does not
8 prohibit the interchange of different brands of the same
9 generically equivalent drug product, when the drug products are
10 not required to bear the legend "Caution: Federal law prohibits
11 dispensing without prescription", provided that the same
12 dosage form is dispensed and there is no greater than 1%
13 variance in the stated amount of each active ingredient of the
14 drug products. A generic drug determined to be therapeutically
15 equivalent by the United States Food and Drug Administration
16 (FDA) shall be available for substitution in Illinois in
17 accordance with this Act and the Pharmacy Practice Act of 1987,
18 provided that each manufacturer submits to the Director of the
19 Department of Public Health a notification containing product
20 technical bioequivalence information as a prerequisite to
21 product substitution when they have completed all required
22 testing to support FDA product approval and, in any event, the
23 information shall be submitted no later than 60 days prior to
24 product substitution in the State.
25 (Source: P.A. 92-112, eff. 7-20-01; 93-841, eff. 7-30-04.)".